Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/25/2869233/0/en/Junshi-Biosciences-Announces-NDA-Acceptance-in-Hong-Kong-for-Toripalimab.html
https://www.globenewswire.com/news-release/2024/04/07/2858828/0/en/Junshi-Biosciences-Announces-Approval-of-the-sNDA-for-Toripalimab-for-the-1st-Line-Treatment-of-Renal-Cancer.html
https://www.globenewswire.com//news-release/2024/02/02/2822598/0/en/Junshi-Biosciences-Announces-Toripalimab-s-NDA-Accepted-by-the-Singapore-Health-Sciences-Authority.html
https://www.globenewswire.com//news-release/2024/01/18/2811217/0/en/Junshi-Biosciences-Announces-JAMA-Publication-of-Results-from-NEOTORCH-a-Randomized-Phase-3-Trial-of-Perioperative-Toripalimab-plus-Chemotherapy-for-Patients-with-Resectable-Non-Sm.html
https://endpts.com/coherus-exits-tigit-deal-with-junshi-three-months-after-surface-oncology-buyout/
https://www.globenewswire.com//news-release/2024/01/10/2806779/0/en/Junshi-Biosciences-Announces-Publication-of-Results-from-TORCHLIGHT-a-Randomized-Phase-3-Trial-of-Toripalimab-for-the-Treatment-of-Metastatic-or-Recurrent-Triple-negative-Breast-Ca.html
https://www.globenewswire.com//news-release/2024/01/02/2802648/0/en/Junshi-Biosciences-Announces-Approval-of-the-Supplemental-New-Drug-Application-for-Toripalimab-as-Perioperative-Treatment-for-Resectable-NSCLC-Patients.html
https://www.globenewswire.com//news-release/2023/12/02/2789608/0/en/Junshi-Biosciences-Announces-New-Chemical-Entity-Application-for-Toripalimab-Accepted-by-Australia-s-TGA.html
https://www.globenewswire.com//news-release/2023/10/27/2768566/0/en/Junshi-Biosciences-Presents-11-Clinical-Trials-of-Toripalimab-at-the-ESMO-Congress-2023.html
https://www.globenewswire.com/news-release/2023/07/20/2707845/0/en/Junshi-Biosciences-Announces-Acceptance-of-the-Supplemental-New-Drug-Application-for-Toripalimab-as-the-First-line-Treatment-of-Extensive-stage-Small-Cell-Lung-Cancer.html